New cancer drug DXC014 enters first human tests

NCT ID NCT07177937

Recruiting now Disease control Sponsor: Hangzhou DAC Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. Participants must have a life expectancy of at least 3 months and be in fairly good health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm prostate cancer small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA OTHER ADVANCED SOLID TUMORS PROSTATE CANCER SMALL CELL LUNG CANCER

Contacts and locations

Locations

Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China
Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China
The Affiliated Hospital of Qingdao University
RECRUITING

Qingdao, Shandong, 266555, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.